SG Americas Securities
ZNTL icon

SG Americas Securities’s Zentalis Pharmaceuticals ZNTL Stock Holding History

SG Americas Securities’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,579
Closed -$48K – 3805
2025
Q3 		$48K Buy
31,579
+8,236
+35% +$12.3K ﹤0.01% 3208
2025
Q2 		$27K Sell
23,343
-761
-3% -$1K ﹤0.01% 2814
2025
Q1 		$38K Sell
24,104
-32,285
-57% -$69.6K ﹤0.01% 3300
2024
Q4 		$171K Buy
56,389
+30,240
+116% +$99.1K ﹤0.01% 2302
2024
Q3 		$96K Buy
26,149
+11,997
+85% +$43.6K ﹤0.01% 3090
2024
Q2 		$58K Buy
+14,152
New +$158K ﹤0.01% 2653
2024
Q1 		– Sell
-152,747
Closed -$2.31M – 3514
2023
Q4 		$2.31M Buy
152,747
+6,252
+4% +$91.2K 0.02% 620
2023
Q3 		$2.94M Buy
146,495
+72,861
+99% +$1.85M 0.03% 520
2023
Q2 		$2.08M Buy
+73,634
New +$1.77M 0.02% 727
2022
Q3 		– Sell
-28,886
Closed -$812K – 3620
2022
Q2 		$812K Buy
28,886
+19,052
+194% +$505K 0.01% 1488
2022
Q1 		$454K Sell
9,834
-9,650
-50% -$521K ﹤0.01% 1949
2021
Q4 		$1.64M Buy
19,484
+773
+4% +$59.8K 0.01% 1257
2021
Q3 		$1.25M Buy
18,711
+7,346
+65% +$424K 0.01% 1708
2021
Q2 		$605K Sell
11,365
-3,966
-26% -$212K ﹤0.01% 1859
2021
Q1 		$665K Buy
15,331
+7,429
+94% +$320K ﹤0.01% 1809
2020
Q4 		$410K Sell
7,902
-43,520
-85% -$1.96M ﹤0.01% 2137
2020
Q3 		$1.68M Buy
51,422
+45,825
+819% +$1.6M 0.01% 851
2020
Q2 		$269K Buy
+5,597
New +$215K ﹤0.01% 2604

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SG Americas Securities's ZNTL Position: Q4 2025 in Review

SG Americas Securities sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 31,579 shares — an estimated $48K sold.

SG Americas Securities first reported a position in ZNTL in Q2 2020 and held it in 18 quarters. The position peaked at $2.94M in Q3 2023. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

  • SG Americas Securities reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • SG Americas Securities sold 31,579 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $48K.
  • SG Americas Securities first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 18 quarters.
  • SG Americas Securities's Zentalis Pharmaceuticals position peaked at $2.94M in Q3 2023.
  • 86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on SG Americas Securities's 13F filing for Q4 2025, filed 9 Jan 2026.